Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure

Thrombosis and Haemostasis

Volumn 102, Issue 3, 2009, Pages 573-580

  Gombos, Tímea ^a   Makó, Veronika ^a   Cervenak, László ^a   Papassotiriou, Jana ^b   Kunde, Jan ^b   Hársfalvi, Jolán ^c   Förhécz, Zsolt ^a   Pozsonyi, Zoltán ^a   Borgulya, Gábor ^d   Jánoskuti, Lívia ^a   Prohászka, Zoltán ^a,d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b BRAHMS Aktiengesellschaft ^*  (Germany)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

ADAMTS13; Endothelial dysfunction; Heart failure; Hepatic failure; Von Willebrand factor

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADAM PROTEINS; AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; COHORT STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RISK; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 70449338756     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-01-0036     Document Type: Article

References (40)

1. Sharma R, Davidoff MN. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail. 2002;8: 165-172. (Pubitemid 34665627)
2. Lip GY, Pearce LA, Chin BS, et al. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation. Heart. 2005; 91: 759-763.
3. Mastroroberto P, Chello M, Perticone F. Elevated circulating levels of von Willebrand factor and D-dimer in patients with heart failure and mechanical prosthesis. Scand J Thorac Cardiovasc Surg. 1996; 30: 77-81. (Pubitemid 26245538)
4. Chong AY, Blann AD, Patel J, et al. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation. 2004;110:1794-1798. (Pubitemid 39302656)
5. Chong AY, Freestone B, Patel J, et al. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol. 2006; 97: 671-675. (Pubitemid 43255037)
6. Chin BS, Conway DS, Chung NA, et al. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis. 2003; 14: 515-521.
7. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002; 99: 3971-3977. (Pubitemid 35332036)
8. Arya M, Lopez JA, Romo GM, et al. Measurement of the binding forces between von Willebrand factor and variants of platelet glycoprotein Ibalpha using optical tweezers. Lasers Surg Med. 2002; 30: 306-312. (Pubitemid 34438564)
9. Feys HB, Canciani MT, Peyvandi F, et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007; 138: 534-540. (Pubitemid 47063038)
10. Besbas N, Karpman D, Landau D, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 2006 ;70: 423-431. (Pubitemid 44141568)
11. Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem. 2001;130: 475-480.
12. Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005; 106: 922-924. (Pubitemid 41076434)
13. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001; 98: 2730-2735.
14. Uemura M, Matsuyama T, Ishikawa M, et al. Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res. 2005; 29 (12 Suppl): 264S-271S. (Pubitemid 43053681)
15. Matsuyama T, Uemura M, Ishikawa M, et al. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res. 2007; 31 (1 Suppl): S27-35. (Pubitemid 46114912)
16. Liu L, Choi H, Bernardo A, et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost. 2005; 3: 2536-2544.
17. Turner N, Nolasco L, Tao Z, et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost. 2006; 4: 1396-1404. (Pubitemid 43756721)
18. Manea M, Kristoffersson A, Schneppenheim R, et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2007; 138: 651-662. (Pubitemid 47206716)
19. Gerritsen HE, Turecek PL, Schwarz HP, et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999; 82: 1386-1389.
20. Molvarec A, Rigo J, Jr., Boze T, et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost. 2009; 101: 305-311.
21. Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem. 1982; 28: 1356-1358.
22. Papassotiriou J, Morgenthaler NG, Struck J, et al. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem. 2006; 52: 1144-1151. (Pubitemid 43794428)
23. Akashi YJ, Springer J, Anker SD. Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. Curr Heart Fail Rep. 2005; 2: 198-203.
24. Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol. 2004; 126: 213-218. (Pubitemid 38961940)
25. Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004; 104: 100-106. (Pubitemid 38879844)
26. Bockmeyer CL, Claus RA, Budde U, et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica. 2008; 93: 137-140. (Pubitemid 351156164)
27. Martin K, Borgel D, Lerolle N, et al. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med. 2007; 35: 2375-2382. (Pubitemid 47476237)
28. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006; 107: 528-534. (Pubitemid 43076375)
29. Bongers TN, de Maat MP, van Goor ML, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke. 2006; 37: 2672-2677.
30. Matsukawa M, Kaikita K, Soejima K, et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol. 2007; 100: 758-763. (Pubitemid 47268262)
31. Crawley JT, Lane DA, Woodward M, et al. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost. 2008; 6: 583-588.
32. Caprioli J, Castelletti F, Bucchioni S, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003; 12: 3385-3395. (Pubitemid 37541083)
33. Sosin MD, Bhatia G, Davis RC, et aö. Congestive heart failure and Virchow's triad: a neglected association. Wien Med Wochenschr. 2003; 153: 411-416.
34. Bowker TJ, Wood DA, Davies MJ. Sudden unexpected cardiac death: methods and results of a national pilot survey. Int J Cardiol. 1995; 52: 241-250. (Pubitemid 126731668)
35. Farb A, Tang AL, Burke AP, et al. Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation. 1995; 92: 1701-1709.
36. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol. 1999; 33: 1424-1426.
37. Gibbs CR, Blann AD, Watson RD, et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation. 2001; 103: 1746-1751.
38. Mahdian R, Rayes J, Girma JP et al. Comparison of FRETS-VWF73 to full-length VWF as a substrate for ADAMTS13 activity measurement in human plasma samples. Thromb Haemost 2006; 95: 1049-1051. (Pubitemid 43933771)
39. Molvarec A, Rigo J Jr, Boze T et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost 2009; 101: 305-311.
40. Plaimauer B, Zimmermann K, Volkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002; 100: 3626-3632. (Pubitemid 35303932)